Questionnaire

1. Biochemically and serologically distinct S. pneumoniae capsule polysaccharides influence:

2. Among the approximately 23 STs causing 80-90% of opportunistic IPD in humans, ST3 is especially problematic as these infections are characterised by severe clinical manifestations and a high mortality.

3. A pneumococcal vaccine that elicits a T cell-dependant response to STs 22F and 33F is:

4. With the introduction of PCV7 (2009) and PCV13 (2011) as part of routine childhood vaccinations in South Africa, laboratory-based IPD surveillance between 2005 and 2019 documented:

5. Following the introduction of PCV7 and PCV13 in South Africa, STs most frequently associated with IPD mortality during 2012-2018 were:

6. A South African province where the incidence of IPD is three-fold greater than the national average is:

7. NICD GERMS-SA 2018-2023 data indicate that in-hospital IPD-related mortality remained high, with most deaths occurring in:

8. PCV15 elicits higher immune responses against ST3 than PCV13 and is indicated for use in ages six weeks through 17 years for the prevention of invasive disease, pneumonia and acute otitis media; PCV15 is not indicated for use in adults ≥18 years.

9. As assessed by rise in OPA titre in adults aged ≥50 years participating in the PNEU-AGE study, PCV15 was superior to PCV13 for:

10. The most commonly reported adverse events with either PCV15 or PCV13 in the PNEU-AGE study were: